心血管疾病中的生活质量. 强调使用β-阻断剂治疗
Circulation
|December 1, 1991
概括
在心血管药物临床试验中使用的β抑制剂可能会影响福祉和精神运动功能. 与非选择性相比,较低剂量和选择性β抑制剂可能会减少不良反应.
科学领域:
- 心脏病学 心脏病学
- 临床药理学 临床药理学
- 心理药理学 心理药理学
背景情况:
- 生活质量 (QoL) 是心血管药物试验的关键结果.
- 贝塔抑制剂广泛用于心血管疾病,现有大量数据.
- 了解它们对 QoL 的影响对于以患者为中心的护理至关重要.
研究的目的:
- 讨论心血管药物的临床试验中的生活质量测量,重点是β-阻断剂.
- 评估β-阻断剂对幸福感和精神运动性能的影响.
- 为了比较不同类型的β抑制剂和其他心血管药物,关于QoL.
主要方法:
- 关于β-阻断剂的现有文献和临床试验数据的审查.
- 对衡量生活质量,幸福感和心理运动测试的研究进行分析.
- 水友性与脂友性和选择性与非选择性β-阻断剂的比较.
主要成果:
- 贝塔抑制剂通常具有较低的严重副作用频率,但可以影响福祉和精神运动测试.
- 与中枢神经系统相关的不良影响可以通过低剂量的β-阻断剂和避免高血峰值度来减少.
- 比非选择性阻断剂,β1选择性阻断剂似乎会引起较少和较少严重的不良反应.
- 在可比剂量的水友性和脂友性β-阻断剂之间没有观察到健康的显著差异.
结论:
- 优化β抑制剂剂量和选择性可以减轻对生活质量的负面影响.
- 与非选择性药物相比,选择性β抑制剂可能提供更好的QoL概况.
- 需要进一步的研究来明确地比较β抑制剂和其他心血管药物类别 (如ACE抑制剂和抗剂) 之间的QoL结果.
更多相关视频
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
04:37Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
相关概念视频
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...